Amicus Therapeutics (NASDAQ: FOLD) reported Q2 EPS of ($0.40), $0.07 worse than the analyst estimate of ($0.33).

2016 Financial Guidance

Cash, cash equivalents, and marketable securities totaled $214.2 million at June 30, 2016. The Company’s balance sheet was strengthened during the second quarter of 2016 with $57.8 million in net proceeds under the existing at-the-marketing (ATM) financing facility and an additional $30 million in debt under an existing debt facility. Following the second quarter close, the Company raised an additional $39.3 million in net proceeds through the ATM facility and has raised the full $100 million allotted for the ATM facility. The Company expects to remain within the original 2016 net cash spend guidance of between $135 million and $155 million.

For earnings history and earnings-related data on Amicus Therapeutics (FOLD) click here.